Department of Medicinal Chemistry, University of Copenhagen, 2 Universitetsparken, 2100 Copenhagen, Denmark.
ChemMedChem. 2011 Apr 4;6(4):725-36. doi: 10.1002/cmdc.201000444. Epub 2011 Jan 18.
A 5-HT₃ receptor agonist based on a benzamide scaffold was identified in a screening of a small commercial compound library, and an elaborate SAR study originating from this hit was performed. The design, synthesis, and functional characterisation of benzamide analogues at the 5-HT₃A receptor yielded substantial information concerning the analogues as 5-HT₃ receptor agonists. However, the potencies of the derived analogues were not significantly improved over that of the initial hit. The benzamide scaffold constitutes a novel type of 5-HT₃ receptor agonist, as it does not possess a positively charged functionality, which is essential for the binding of all orthosteric ligands to the receptor. Preliminary investigations suggest that the compounds may exert their effects on 5-HT₃ receptors by binding to an allosteric site in the receptor complex.
在对一个小型商业化合物库进行筛选时,发现了一种基于苯甲酰胺骨架的 5-HT₃受体激动剂,并对该命中化合物进行了详尽的 SAR 研究。对 5-HT₃A 受体的苯甲酰胺类似物进行设计、合成和功能表征,为类似物作为 5-HT₃ 受体激动剂提供了大量信息。然而,衍生类似物的效力并没有比最初的命中化合物显著提高。苯甲酰胺骨架构成了一种新型的 5-HT₃ 受体激动剂,因为它不具有正电荷官能团,而这对于所有变构配体与受体的结合是必需的。初步研究表明,这些化合物可能通过与受体复合物中的变构位点结合来发挥作用。